诺和诺德：市场先生已计入成功，但现在定论为时尚早 (NYSE:NVO)
· seekingalpha.com
由于 Ozempic/Rybelsus 的疲软表现冲击了营收，尽管现金流强劲且估值较低，诺和诺德仍被评为持有。点击查看更多关于 NVO 股票的信息。
Crude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, lea...